BMEA on Nasdaq
Biomea Fusion, Inc.
In its 2026 annual report the company says: “We are a clinical‑stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases.”3 It is headquartered in San Carlos, California.1 Its shares trade on Nasdaq under the symbol BMEA.1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerBMEA on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersSan Carlos, California1
- Incorporated inDE2
- Business address1599 Industrial Road, San Carlos, Ca 940702
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
We are a clinical‑stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $62.0M | $118.1M | $102.5M |
| General and administrative | $19.3M | $26.0M | $23.6M |
| Impairment of long-lived assets | $2.2M | $0 | $0 |
| Total operating expenses | $83.5M | $144.1M | $126.1M |
| Loss from operations | -$83.5M | -$144.1M | -$126.1M |
| Change in fair value of common warrant liability | $19.9M | $0 | $0 |
| Interest and other income, net | $1.9M | $5.6M | $8.9M |
| Net loss | -$61.8M | -$138.4M | -$117.3M |
| Unrealized gain on investments, net | $1.0K | ||
| Comprehensive loss | -$61.8M | -$138.4M | -$117.3M |
| Net loss per common share, basic | -$1.18 | -$3.83 | -$3.44 |
| Net loss per common share, diluted | -$1.18 | -$3.83 | -$3.44 |
| Weighted-average number of common shares used to compute basic net loss per common share | 52.2M shares | 36.1M shares | 34.1M shares |
| Weighted-average number of common shares used to compute diluted net loss per common share | 52.2M shares | 36.1M shares | 34.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $55.8M | $58.3M | $176.9M | |
| Prepaid expenses and other current assets | $2.2M | $10.1M | ||
| Total current assets | $58.0M | $68.3M | ||
| Property and equipment, net | $153.0K | $3.8M | ||
| Restricted cash | $369.0K | $369.0K | $370.0K | |
| Other non-current assets | $0 | $619.0K | ||
| Operating lease right-of-use assets | $0 | $6.9M | ||
| Total assets | $58.6M | $79.9M | ||
| Accounts payable | $3.2M | $12.9M | ||
| Accrued expenses and other current liabilities | $6.4M | $6.7M | ||
| Operating lease liabilities, current | $1.5M | $2.1M | ||
| Total current liabilities | $11.1M | $21.7M | ||
| Operating lease liabilities, non-current | $128.0K | $6.7M | ||
| Warrant liability, non-current | $17.8M | $0 | ||
| Total liabilities | $29.0M | $28.4M | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 72,299,440 and 36,310,713 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $7.0K | $4.0K | ||
| Additional paid-in capital | $478.6M | $438.8M | ||
| Accumulated deficit | -$449.0M | -$387.3M | ||
| Total stockholders' equity | $29.6M | $51.6M | $169.2M | $108.5M |
| Total liabilities and stockholders' equity | $58.6M | $79.9M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 72.3M shares | 36.3M shares | ||
| Common stock, shares outstanding | 72.3M shares | 36.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $55.8M | $58.3M | $176.9M | |
| Prepaid expenses and other current assets | $2.2M | $10.1M | ||
| Total current assets | $58.0M | $68.3M | ||
| Property and equipment, net | $153.0K | $3.8M | ||
| Restricted cash | $369.0K | $369.0K | $370.0K | |
| Other non-current assets | $0 | $619.0K | ||
| Operating lease right-of-use assets | $0 | $6.9M | ||
| Total assets | $58.6M | $79.9M | ||
| Accounts payable | $3.2M | $12.9M | ||
| Accrued expenses and other current liabilities | $6.4M | $6.7M | ||
| Operating lease liabilities, current | $1.5M | $2.1M | ||
| Total current liabilities | $11.1M | $21.7M | ||
| Operating lease liabilities, non-current | $128.0K | $6.7M | ||
| Warrant liability, non-current | $17.8M | $0 | ||
| Total liabilities | $29.0M | $28.4M | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 72,299,440 and 36,310,713 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $7.0K | $4.0K | ||
| Additional paid-in capital | $478.6M | $438.8M | ||
| Accumulated deficit | -$449.0M | -$387.3M | ||
| Total stockholders' equity | $29.6M | $51.6M | $169.2M | $108.5M |
| Total liabilities and stockholders' equity | $58.6M | $79.9M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 72.3M shares | 36.3M shares | ||
| Common stock, shares outstanding | 72.3M shares | 36.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$61.8M | -$138.4M | -$117.3M |
| Depreciation expense | $1.4M | $1.7M | $1.5M |
| Non-cash operating lease expense | $1.8M | $2.8M | $2.7M |
| Stock-based compensation expense | $9.5M | $19.1M | $14.1M |
| Net amortization of premiums and accretion of discounts on investments | $1.0K | ||
| Change in fair value of warrant liability | -$19.9M | $0 | $0 |
| Impairment of long-lived assets | $2.2M | $0 | $0 |
| Prepaid expenses and other current assets | $7.8M | -$7.7M | $2.5M |
| Other non-current assets | $619.0K | $4.9M | -$2.4M |
| Accounts payable | -$9.7M | $6.1M | $2.6M |
| Accrued expenses and other current liabilities | -$255.0K | -$6.9M | $1.9M |
| Operating lease liabilities | -$2.2M | -$1.5M | -$2.2M |
| Net cash used in operating activities | -$70.4M | -$119.9M | -$96.6M |
| Purchase of property and equipment | -$362.0K | -$3.4M | |
| Maturities of investments | $1.1M | ||
| Net cash (used in) provided by investing activities | -$362.0K | -$2.2M | |
| Proceeds from issuance of common stock under at the market equity offering program, net of offering costs | $4.9M | ||
| Proceeds from issuance of common stock, common warrants and pre-funded warrants, net of offering costs | $62.8M | $161.8M | |
| Proceeds from stock options exercised and purchases under the employee stock purchase plan | $159.0K | $1.7M | $2.0M |
| Net cash provided by financing activities | $67.9M | $1.7M | $163.8M |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -$2.5M | -$118.6M | $65.0M |
| Acquisition of operating lease right-of-use assets | $6.0M | ||
| Acquisition of property and equipment in accounts payable and accrued liabilities | $7.0K | ||
| Remeasurement of operating lease right-of-use assets and lease liability | $5.1M | $5.7M |
No quarter-by-quarter statement was filed.
Corporate structure
Biomea Fusion, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Biomea Fusion, Inc.
- CVI Investments, Inc. Filed SCHEDULE 13G/A on Biomea Fusion, Inc., latest Feb 17, 2026 (3 filings since Jun 25, 2025)
- Blue Owl Capital Filed SCHEDULE 13G on Biomea Fusion, Inc., latest Feb 12, 2026 (3 filings since Aug 11, 2025)
- Rainer M. Erdtmann Filed SCHEDULE 13G/A on Biomea Fusion, Inc., latest Feb 6, 2026 (5 filings since Feb 11, 2022)
- Janus Henderson Group Ltd. Filed SCHEDULE 13G on Biomea Fusion, Inc., latest Dec 8, 2025 (4 filings since Feb 10, 2022)
- Cormorant Asset Management, LP Filed SCHEDULE 13D/A on Biomea Fusion, Inc., latest Oct 24, 2025 (3 filings since Jul 22, 2025)
- BlackRock Filed SCHEDULE 13G/A on Biomea Fusion, Inc., latest Jul 16, 2025 (4 filings since Feb 4, 2022)
- BAKER BROS. ADVISORS LP Filed SCHEDULE 13G/A on Biomea Fusion, Inc., latest Feb 14, 2025 (3 filings since Feb 14, 2023)
- Laurion Capital Management LP Filed SC 13G/A on Biomea Fusion, Inc., latest Nov 12, 2024 (2 filings since Feb 8, 2024)
- State Street Corporation Filed SC 13G/A on Biomea Fusion, Inc., latest Jul 10, 2024 (2 filings since Apr 10, 2024)
- Thomas Andrew Butler Filed SC 13G/A on Biomea Fusion, Inc., latest Feb 12, 2024 (3 filings since Feb 11, 2022)
- FMR LLC Filed SC 13G/A on Biomea Fusion, Inc., latest Feb 9, 2024 (2 filings since May 10, 2023)
- Cormorant Global Healthcare Master Fund, LP Filed SC 13D/A on Biomea Fusion, Inc., latest Apr 3, 2023
- Biomea Fusion, Inc. San Carlos, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Biomea Fusion, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.2M8 Dec 31, 2025 | $7.9M8 Dec 31, 2024 | −85.4% |
| Accumulated depreciation | $1.0M8 Dec 31, 2025 | $4.2M8 Dec 31, 2024 | −75.9% |
| Property and equipment, net | $153.0K8 Dec 31, 2025 | $3.8M8 Dec 31, 2024 | −95.9% |
| Operating-lease assets (leased space) | $08 Dec 31, 2025 | $6.9M8 Dec 31, 2024 | −100.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $55.8M8 Dec 31, 2025 | $58.3M8 Dec 31, 2024 | −4.2% |
| Debt securities available for sale | $56.0M7 Dec 31, 2024 | $174.4M7 Dec 31, 2023 | −67.9% |
Properties, in its own words
We currently lease approximately 18,796 square feet of office space in San Carlos, California under two leases which expire in January 2027. We believe these facilities are sufficient to meet our near-term needs and that any additional space we may require will be available on commercially reasonable terms.
Item 2 of the 10-K filed Mar 24, 2026.3
Leadership
Who has led Biomea Fusion, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerMichael J.m. Hitchcock Mar 28, 2025 to now11
- Chief executive officerThomas Andrew Butler Apr 15, 2021 to Jan 18, 202412
- PresidentRainer M. Erdtmann Apr 15, 2021 to Jan 18, 202413
- Chief financial officerFranco Valle Aug 5, 2021 to Dec 2, 202414
- Chief operating officerRainer M. Erdtmann Apr 15, 2021 to Jan 18, 202413
Board members and other officers (12)
- OfficerRainer M. Erdtmann Aug 13, 2025 to now15
- Chief Medical OfficerJuan Pablo Frias Sep 1, 2023 to Jun 12, 202416
- EVP of FinanceSunny Ryan Apr 15, 2021 to Apr 15, 202117
- Board memberJulianne Averill Jul 24, 2025 to now18
- Board memberElizabeth Faust Jun 24, 2022 to now19
- Board memberBihua Chen Apr 15, 2021 to now20
- Board memberEric Aguiar Apr 15, 2021 to now21
- Board memberMichael J.m. Hitchcock Apr 15, 2021 to now22
- Board memberRainer M. Erdtmann Apr 15, 2021 to now13
- Board memberSotirios Stergiopoulos Apr 15, 2021 to Sep 21, 202123
- Board memberThomas Andrew Butler Apr 15, 2021 to Jan 18, 202412
- Board memberSumita Ray Jun 21, 2021 to now24
Timeline
- Oct 14, 20268-K Regulation FD disclosure; Other events25
- Sep 22, 20268-K Other events26
- Aug 5, 20268-K Financial statements and exhibits27
- Jun 11, 20268-K Shareholder vote28
- May 11, 20268-K Results of operations29
- Apr 28, 20268-K Regulation FD disclosure; Other events30
- Mar 24, 20268-K Results of operations31
- Feb 25, 20268-K Regulation FD disclosure32
- Jan 14, 20268-K Regulation FD disclosure; Other events33
- Nov 4, 20258-K Results of operations34
- Oct 7, 20258-K Entered a material agreement; Other events35
- Oct 6, 20258-K Other events36
- Mar 28, 2025New chief executive Michael J.m. Hitchcock becomes CEO11
- Apr 15, 2021New chief executive Thomas Andrew Butler becomes CEO12
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.27) a share, on Nov 4, 2025.37
When it reported results
- May 11, 2026Reported quarterly or annual results29
- Mar 24, 2026Reported quarterly or annual results31
- Nov 4, 2025Reported quarterly or annual results34
- Aug 5, 2025Reported quarterly or annual results38
- May 5, 2025Reported quarterly or annual results39
- Mar 31, 2025Reported quarterly or annual results40
- Oct 29, 2024Reported quarterly or annual results41
- Jul 31, 2024Reported quarterly or annual results42
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
233 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 65 major events, 74 insider forms, 36 large holders, 38 other. The latest 20:
- Oct 14, 20268-K EDGAR
- Sep 22, 2026424B5 EDGAR
- Sep 22, 20268-K EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 11, 20268-K EDGAR
- May 11, 202610-Q EDGAR
- May 11, 20268-K EDGAR
- Apr 28, 20268-K EDGAR
- Apr 27, 2026DEF 14A EDGAR
- Apr 27, 2026ARS EDGAR
- Apr 3, 20264 EDGAR
- Apr 3, 20264 EDGAR
- Mar 24, 202610-K EDGAR
- Mar 24, 20268-K EDGAR
- Feb 25, 20268-K EDGAR
The 233 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
21 open-market trades by officers, directors and large owners since October 2021: 11 buys and 10 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | Erdtmann Rainer MSee Remarks | Buy | 30,000 | $1.43 | $42.9K | Form 4 |
| Dec 2, 2025 | Hitchcock Michael J.M.Interim CEO | Buy | 100,000 | $0.99 | $99.0K | Form 4 |
| Dec 1, 2025 | Erdtmann Rainer MSee Remarks | Buy | 10,000 | $1.05 | $10.5K | Form 4 |
| Nov 28, 2025 | Erdtmann Rainer MSee Remarks | Buy | 40,000 | $1.10 | $44.0K | Form 4 |
| Sep 30, 2024 | Hitchcock Michael J.M.Interim CEO | Buy | 10,000 | $10.06 | $100.6K | Form 4 |
| Jun 11, 2024 | Valle FrancoChief Financial Officer | Buy | 12,509 | $4.43 | $55.4K | Form 4 |
| Jun 1, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 50,000 | $34.56 | $1.7M | Form 4 |
| May 31, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 75,000 | $33.81 | $2.5M | Form 4 |
| May 12, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 25,000 | $33.84 | $846.0K | Form 4 |
| May 9, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 150,000 | $34.50 | $5.2M | Form 4 |
| May 8, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 100,000 | $33.99 | $3.4M | Form 4 |
| Apr 20, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 200,000 | $29.12 | $5.8M | Form 4 |
| Mar 31, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 200,000 | $31.25 | $6.2M | Form 4 |
| Mar 31, 2023 | A2A Pharmaceuticals, Inc.10% owner | Sale | 200,000 | $31.25 | $6.2M | Form 4 |
| Mar 30, 2023 | Cormorant Global Healthcare Master Fund, LP | Buy | 400,000 | $30.00 | $12.0M | Form 4 |
| Nov 14, 2022 | Hitchcock Michael J.M.Interim CEO | Buy | 5,000 | $7.93 | $39.6K | Form 4 |
| Nov 11, 2022 | Valle FrancoChief Financial Officer | Buy | 4,100 | $7.63 | $31.3K | Form 4 |
| Aug 16, 2022 | A2A Pharmaceuticals, Inc.10% owner | Buy | 30,684 | $13.87 | $425.6K | Form 4 |
| Jul 21, 2022 | A2A Pharmaceuticals, Inc.10% owner | Sale | 34,658 | $11.21 | $388.5K | Form 4 |
| Jun 24, 2022 | A2A Pharmaceuticals, Inc.10% owner | Sale | 34,658 | $11.76 | $407.6K | Form 4 |
All 21 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- CVI Investments, Inc.SCHEDULE 13G/A, 3 filings Jun 25, 2025 to Feb 17, 202643
- Blue Owl CapitalSCHEDULE 13G, 3 filings Aug 11, 2025 to Feb 12, 202644
- Rainer M. ErdtmannSCHEDULE 13G/A, 5 filings Feb 11, 2022 to Feb 6, 202645
- Janus Henderson Group Ltd.SCHEDULE 13G, 4 filings Feb 10, 2022 to Dec 8, 202546
- Cormorant Asset Management, LPSCHEDULE 13D/A, 3 filings Jul 22, 2025 to Oct 24, 202547
- BlackRockSCHEDULE 13G/A, 4 filings Feb 4, 2022 to Jul 16, 202548
- BAKER BROS. ADVISORS LPSCHEDULE 13G/A, 3 filings Feb 14, 2023 to Feb 14, 202549
- Laurion Capital Management LPSC 13G/A, 2 filings Feb 8, 2024 to Nov 12, 202450
- State Street CorporationSC 13G/A, 2 filings Apr 10, 2024 to Jul 10, 202451
- Thomas Andrew ButlerSC 13G/A, 3 filings Feb 11, 2022 to Feb 12, 202452
- FMR LLCSC 13G/A, 2 filings May 10, 2023 to Feb 9, 202453
- Cormorant Global Healthcare Master Fund, LPSC 13D/A, 1 filing Apr 3, 202354
- Boxer Capital, LLCSC 13G/A, 1 filing Feb 14, 202255
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Michael J.M. Hitchcock, Ph.D.Interim Chief Executive Officer and Principal Executive Officer | 76 | $486.7K | $2.6M56 |
| 2025 | Rainer (Ramses) ErdtmannChief Operating Officer, President, Principal Financial Officer and Principal Accounting Officer | 62 | $489.6K | $2.2M56 |
| 2025 | Thomas ButlerFormer Chief Executive Officer and Former Chairman of the Board | $662.0K56 | ||
| 2025 | Juan Pablo Frias, M.D.Former Chief Medical Officer | $325.0K | $549.0K56 | |
| 2024 | Thomas ButlerFormer Chief Executive Officer and Former Chairman of the Board | $633.6K | $5.1M56 | |
| 2024 | Rainer (Ramses) ErdtmannChief Operating Officer, President, Principal Financial Officer and Principal Accounting Officer | 62 | $489.6K | $2.0M56 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 62. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 8,814,946 | $13.0M | 0.0% | +1,587 |
| Vanguard Capital Management LLC | 2,829,927 | $4.2M | 0.0% | +232,627 |
| Marshall Wace, Llp | 2,049,802 | $3.0M | 0.0% | +851,251 |
| Aisling Capital Management LP | 2,048,757 | $3.0M | 0.6% | No change |
| Renaissance Technologies LLC | 1,455,474 | $2.1M | 0.0% | +142,676 |
| Fideuram - Intesa Sanpaolo Private Banking S.p.a. | 723,176 | $1.1M | 0.0% | +166,140 |
| BlackRock, Inc. | 715,445 | $1.1M | 0.0% | +74,010 |
| Geode Capital Management, LLC | 708,854 | $1.0M | 0.0% | +160,668 |
| Susquehanna International Group, Llp | 612,735 | $900.7K | 0.0% | −17,130 |
| Mariner, LLC | 594,726 | $874.2K | 0.0% | −59,852 |
| Jane Street Group, LLC | 458,289 | $673.7K | 0.0% | +182,634 |
| UBS Group AG | 444,728 | $653.8K | 0.0% | −70,827 |
| XTX Topco Ltd | 406,879 | $598.1K | 0.0% | −123,663 |
| Two Sigma Investments, LP | 384,459 | $565.2K | 0.0% | −4,237 |
| Morgan Stanley | 367,021 | $539.5K | 0.0% | +20,279 |
| Vanguard Fiduciary Trust Co | 338,345 | $497.4K | 0.0% | +2,230 |
| MAI Capital Management | 289,100 | $425.0K | 0.0% | +200,000 |
| State Street Corp | 257,315 | $378.3K | 0.0% | +49,300 |
| LMR Partners LLP | 200,000 | $261.0K | 0.0% | No change |
| Northern Trust Corp | 128,526 | $188.9K | 0.0% | −80,439 |
| Headlands Technologies LLC | 111,349 | $163.7K | 0.0% | +5,750 |
| Marex Group Ltd | 100,000 | $147.0K | 0.0% | No change |
| Goldman Sachs Group Inc | 93,757 | $137.8K | 0.0% | +18,018 |
| Bridgeway Capital Management, LLC | 84,600 | $124.4K | 0.0% | No change |
| Jain Global LLC | 75,698 | $111.3K | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Biomea Fusion, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBiomea Fusion, Inc.1
- CIK0001840439
- Employer ID (EIN)82-25201343
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address1599 Industrial Road, San Carlos, CA 940701
- Phone(650) 980-90991
- Shares outstanding72,483,852 as of Jul 31, 202610
- Public float$93.6M as of Jun 30, 20253
- AuditorDeloitte & Touche LLP, San Francisco, CA PCAOB ID 34; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceJan 15, 20211
- Filings290 in all: 4 (80), 8-K (73), 10-Q (17), 3 (14), SC 13G/A (12), SC 13G (11), 424B5 (8), CORRESP (8)1
All 34 form types
SCHEDULE 13G/A (7), UPLOAD (7), S-8 (6), 10-K (5), DEF 14A (5), ARS (4), SCHEDULE 13G (4), 144 (3), EFFECT (3), SCHEDULE 13D/A (3), 4/A (2), 5 (2), S-1/A (2), S-3 (2), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), DEFA14A (1), DRS (1), PRE 14A (1), S-1 (1), S-1MEF (1), SC 13D (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 24, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 27, 2026
Latest 8-K (8-K) Oct 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value | BMEA | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Mar 24, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Biomea Fusion, Inc. names in Item 1A of its 10-K filed Mar 24, 2026: 75 risks under these headings, as written.3
- Risks Related to Our Limited Operating History, Business, Financial Condition, Results of Operations, and Need for Additional Capital
- We have a limited operating history, limited experience in conducting clinical trials, have not completed the clinical development of any product candidates, have no products approved for commercial sale, and have not generated any revenue, which may make it difficult for you to evaluate our current business and likelihood of success and viability.
- We have incurred significant net losses in each period since our inception, and we expect to incur significant net losses for the foreseeable future.
- We have not generated any revenue from our product candidates and may never generate revenue or be profitable. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery and development of our product candidates.
- Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain indications. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and product development programs or future commercialization efforts.
- There is substantial doubt about our ability to continue as a going concern.
- Volatility in capital markets and lower market prices for many securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.
- Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.
- Risks Related to Product Development
- Our discovery and development activities are focused on the development of novel small molecule therapies, initially targeted at menin, to treat patients with diabetes and obesity, and the approach we are taking to discover and develop such product candidates is novel, may never lead to marketable products and may not ultimately represent a significant market.
- We are early in our development efforts and are substantially dependent on our product candidates, icovamenib and BMF-650. If we are unable to advance icovamenib, BMF-650 or any other product candidates through clinical development, obtain regulatory approval and ultimately commercialize icovamenib, BMF-650 or any other product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.
The other 64 risks
- Preclinical and clinical drug development is a lengthy and expensive process, with an uncertain outcome. Our preclinical and clinical programs may experience delays or may never be initiated or completed, which would adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.
- The results of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities. Successful preclinical studies and clinical trials cannot provide assurance of successful commercialization.
- We face risks related to global health emergencies such as a pandemic, epidemic, or outbreak of an infectious disease, which could materially adversely impact our business, results of operations, and financial condition, including our preclinical studies and clinical trials.
- If we experience delays or difficulties in the enrollment and/or retention of eligible participants in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.
- The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.
- The incidence and prevalence for target patient populations of icovamenib and BMF-650 are based on estimates and third-party sources. If the market opportunities for icovamenib and BMF-650 or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.
- We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
- Our novel small molecule product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational product candidates that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
- Interim, “top-line”, and preliminary data from our clinical trials that we announce or publish from time to time may change as more participants data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, and others in the medical community.
- Coverage and reimbursement of newly-approved products from third-party payors is uncertain. Our product candidates may become subject to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, either of which would adversely affect our business. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
- If product liability lawsuits are brought against us, we may incur substantial liabilities, which may not be sufficiently covered by insurance, and may be required to limit commercialization of our product candidates.
- We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.
- Risks Related to Regulatory Process and Other Legal Compliance Matters
- The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.
- A condition or disease we are conducting or plan to conduct clinical trials for may not be a rare disease or condition that is eligible for orphan drug designation or we may not be able to obtain orphan drug designation or obtain or maintain the benefits associated with orphan drug designation, such as orphan drug exclusivity and, even if we do, that exclusivity may not prevent the FDA or other comparable foreign regulatory authorities, from approving competing products.
- A Breakthrough Therapy designation or Fast Track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United States.
- Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval.
- We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.
- Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
- Changes in funding or disruptions at the FDA, the SEC and other government agencies caused by reduction in staffing, funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
- Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
- The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
- Our employees, independent contractors, consultants, principal investigators, CROs, suppliers, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
- We are or may become subject to stringent and changing laws, regulations, contractual obligations, and other obligations relating to privacy, data protection, and information security. The actual or perceived failure by us or our partners, customers, vendors, third-party payors or other related third parties to comply with such obligations could harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business.
- Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.
- We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.
- Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.
- Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business
- We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
- In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.
- Business disruptions could materially adversely affect our future revenue and financial condition and increase our costs and expenses.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.
- Changes in tax law may adversely affect us or our investors.
- A portion of our chemistry-based product development and sourcing of certain manufacturing raw materials for our product candidates takes place outside the United States through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations.
- Risks Related to Reliance on Third Parties
- We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
- We currently, and may in the future, depend on single-source suppliers for some of the ingredients, components and materials used in, and the manufacturing processes required to develop, our product candidates.
- If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.
- We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.
- If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
- Risks Related to Intellectual Property
- If we are unable to obtain, maintain, enforce and adequately protect our patents and other intellectual property rights with respect to our technology and product candidates, or if the scope of our patents or other intellectual property rights are not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology or product candidates may be adversely affected.
- Our success depends in part on our ability to protect our intellectual property rights. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.
- Any issued patents we may own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO.
- We may become involved in lawsuits or litigation at the USPTO to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
- Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our technology, products and product candidates.
- We may be subject to claims challenging the inventorship of our patents and other intellectual property.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain. Defending against such lawsuits will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.
- Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers.
- If we fail to comply with our obligations in any future agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with any licensors, we could lose license rights that are important to our business.
- Intellectual property rights do not necessarily address all potential threats.
- Risks Related to Our Common Stock
- The price of our stock has been and is likely to continue to be volatile, and you may not be able to resell shares of our common stock at or above the price you paid.
- Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
- A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly.
- Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or upon the exercise of outstanding warrants, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
- Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities.
- Our management and directors own our stock and may be able to exert influence over matters subject to stockholder approval.
- We do not intend to pay dividends on our capital stock, so any returns will be limited to the value of our stock.
- Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.
- Our amended and restated certificate of incorporation and amended and restated bylaws provide for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
Legal proceedings
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARRainer M. Erdtmann, President
- 14
- 15SEC EDGARRainer M. Erdtmann, Officer
- 16
- 17SEC EDGARSunny Ryan, EVP of Finance
- 18SEC EDGARJulianne Averill, Board member
- 19SEC EDGARElizabeth Faust, Board member
- 20SEC EDGARBihua Chen, Board member
- 21SEC EDGAREric Aguiar, Board member
- 22SEC EDGARMichael J.m. Hitchcock, Board member
- 23SEC EDGARSotirios Stergiopoulos, Board member
- 24SEC EDGARSumita Ray, Board member
- 25
- 26SEC EDGAROther events
- 27SEC EDGARFinancial statements and exhibits
- 28SEC EDGARShareholder vote
- 29SEC EDGARResults of operations
- 30
- 31SEC EDGARResults of operations
- 32SEC EDGARRegulation FD disclosure
- 33
- 34SEC EDGARResults of operations
- 35
- 36SEC EDGAROther events
- 37NasdaqNasdaq calendar
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56